Lyell Immunopharma, Inc. announced promising clinical data for its CAR T-cell therapy candidate LYL314, showing an 88% overall response rate and a 72% complete response rate in patients with relapsed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback